Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748120 | 0.83 | GAA (0.37) | GAACYP4F2CYP4A11RETALDH1A1 | |
| SCHEMBL14330465 | 0.81 | GAA (0.36) | GAACYP4F2CYP4A11RET | |
| SCHEMBL21152701 | 0.81 | GAA (0.51) | GAACYP4F2CYP4A11RETDRD1 | |
| SCHEMBL21002088 | 0.78 | GAA (0.49) | GAACYP4F2CYP4A11RETALDH1A1 | |
| SCHEMBL17675453 | 0.78 | GAA (0.49) | GAACYP4F2CYP4A11RETDRD1 | |
| SCHEMBL25389805 | 0.75 | GAA (0.46) | GAACYP4F2CYP4A11RETDRD1 | |
| SCHEMBL17675672 | 0.74 | GAA (0.45) | GAACYP4F2CYP4A11RETDRD1 | |
| SCHEMBL15334772 | 0.72 | GAA (0.40) | GAACYP4F2CYP4A11RETALDH1A1 | |
| SCHEMBL29138834 | 0.71 | GAA (0.40) | GAACYP4F2CYP4A11DRD1 | |
| SCHEMBL1040373 | 0.71 | GAA (0.39) | GAACYP4F2CYP4A11RETALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835423-B2 | Azepine inhibitors of janus kinases | INCYTE CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | GAA 3002/4885CYP4F2 4265/4885CYP4A11 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.